Available Technologies

Browse Penn-owned technologies available for licensing.


Search Results - jonathan epstein

3 Results Sort By:
Pharmaceutical therapeutic for the treatment of respiratory diseases
Histone deacetylase (HDAC) inhibitors such as Trichostatin A to treat bronchoconstrictive diseases including asthma and chronic obstructive pulmonary disorder (COPD) Technology Overview: Asthma and COPD are diseases of variable airflow obstruction affecting more than 40 million Americans. Although some patients respond to conventional therapies,...
Published: 11/14/2019   |   Inventor(s): Jonathan Epstein, Reynold Panettieri
Category(s): Therapeutics & Vaccines
Histone deacetylase (HDAC) and DNA methyltransferase (DNMT) inhibitors for preventative cardiac care and ischemic injury treatment
HDAC and DNMT Inhibitors such as Trichostatin A (TSA) and 5-aza-cytidine are preventative therapies and reduce myocardial infarct volume following cardiac events Technology Overview: Every 40 seconds, someone in the United States has a heart attack. Although several therapeutic options for heart attack recovery exist, ischemic injuries are responsible...
Published: 11/14/2019   |   Inventor(s): Jonathan Epstein, Peter Gruber, Ibrahim Abdullah
Category(s): Therapeutics & Vaccines
CAR-T cell therapy for heart diseases
CAR-T cells targeting cardiac fibroblasts to reduce pathological fibrosis and improve cardiac function Technology Overview: Most forms of heart failure are accompanied by cardiac fibrosis causing a “stiff heart” and contractile dysfunction, which most commonly refers to the excessive deposition of extracellular matrix in the cardiac...
Published: 10/23/2019   |   Inventor(s): Haig Aghajanian, Jonathan Epstein
Category(s): Therapeutics & Vaccines